WEST Search History

Hide Items | Restore | Clear | Cancel

DATE: Friday, April 07, 2006

Hide?	Set Name	Query	Hit Count
		DB=PGPB; THES=ASSIGNEE; PLUR=YES; OP=ADJ	
☐	L7	(HPTP or protein adj3 tyrosine phosphatase) same (crystal or x-ray)	44
		DB=USPT,USOC,EPAB,JPAB,DWPI; THES=ASSIGNEE; PLUR=YES; OP=ADJ	
☐	L6	(HPTP or protein adj3 tyrosine phosphatase) same (crystal or x-ray)	34
☐	L5	L4 and atomic coordinate	1
☐	L4	L3 and (crystal or x-ray)	170
☐	L3	L2 and catalytic domain	329
☐	L2	HPTP or protein adj3 tyrosine phosphatase	1491
☐	L1	HPTP	72

END OF SEARCH HISTORY

Hit List

First Hit | Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Search Results - Record(s) 1 through 1 of 1 returned.

☐ 1. Document ID: US 6631332 B2

Using default format because multiple data bases are involved.

L5: Entry 1 of 1 File: USPT Oct 7, 2003

US-PAT-NO: 6631332
DOCUMENT-IDENTIFIER: US 6631332 B2

TITLE: Methods for using functional site descriptors and predicting protein function

DATE-ISSUED: October 7, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Skolnick; Jeffrey	San Diego	CA		
Fetrow; Jacquelyn S.	San Diego	CA		

US-CL-CURRENT: 702/19; 435/4, 436/86, 702/27

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Terms	Documents
L4 and atomic coordinate	1

Display Format: - Change Format

Previous Page Next Page Go to Doc#

Hit List

First Hit | Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Search Results - Record(s) 1 through 30 of 34 returned.

☐ 1. Document ID: US 7005445 B2

Using default format because multiple data bases are involved.

L6: Entry 1 of 34 File: USPT Feb 28, 2006

US-PAT-NO: 7005445
DOCUMENT-IDENTIFIER: US 7005445 B2

TITLE: Protein kinase and phosphatase inhibitors and methods for designing them

DATE-ISSUED: February 28, 2006

PRIOR-PUBLICATION:

DOC-ID	DATE
US 20030166615 A1	September 4, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hangauer, Jr.; David G.	Amherst	NY		US
El-Araby; Moustafa E.	Plainsboro	NJ		US
Milkiewicz; Karen L.	Exton	PA		US

US-CL-CURRENT: 514/419; 548/469

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 2. Document ID: US 6797513 B2

L6: Entry 2 of 34 File: USPT Sep 28, 2004

US-PAT-NO: 6797513
DOCUMENT-IDENTIFIER: US 6797513 B2

TITLE: Nucleic acid encoding CLK2 protein kinases

DATE-ISSUED: September 28, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ullrich; Axel	Munchen			DE
Nayler; Oliver	Graefehing			DE

US-CL-CURRENT: 435/325; 435/194, 435/252.3, 435/254.11, 435/320.1, 435/69.1, 530/300, 530/350, 536/23.1, 536/23.5

ABSTRACT:

The present invention relates to nucleic acid molecules encoding mCLK2, mCLK3, and mCLK4 polypeptides, nucleic acid molecules-encoding portions of their amino acid sequences, nucleic acid vectors harboring such nucleic acid molecules, cells containing such nucleic acid vectors, purified polypeptides encoded by such nucleic acid molecules, and antibodies to such polypeptides. Also included are assays that contain at least one CLK protein kinase related molecule. Diagnosis and treatment of an abnormal condition related to RNA splicing or cell proliferation in an organism by using a CLK protein kinase related molecule or compound are disclosed. A method of using a CLK protein kinase related molecule or compound as a contraceptive to reproduction in male organisms is also disclosed.

8 Claims, 7 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 7

☐ 3. Document ID: US 6797501 B2

L6: Entry 3 of 34 File: USPT Sep 28, 2004

US-PAT-NO: 6797501
DOCUMENT-IDENTIFIER: US 6797501 B2

TITLE: Protein tyrosine phosphatase PTP20 and related products and methods

DATE-ISSUED: September 28, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Aoki; Naohita	Nagoya			JP
Ullrich; Axel	Martinsried			DE

US-CL-CURRENT: 435/194; 435/195, 435/196, 435/252.3, 435/320.1, 530/300, 530/350, 536/23.2

ABSTRACT:

The present invention relates to a novel polypeptide, PTP20, and to nucleic acid molecules encoding the polypeptide. The invention also relates to nucleic acid molecules encoding portions of the phosphatase, nucleic acid vectors containing PTP20 related nucleic acid molecules, recombinant cells containing such nucleic acid vectors, polypeptides purified from such recombinant cells, antibodies to such polypeptides, and methods of identifying compounds that bind PTP20 or abrogate its interactions with natural binding partners. Also disclosed are methods for diagnosing abnormal conditions in an organism with PTP20 related molecules or compounds.

17 Claims, 0 Drawing figures

Exemplary Claim Number: 1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 4. Document ID: US 6780625 B2

L6: Entry 4 of 34 File: USPT Aug 24, 2004

US-PAT-NO: 6780625
DOCUMENT-IDENTIFIER: US 6780625 B2

TITLE: Glycogen synthase kinase-3 inhibitors

DATE-ISSUED: August 24, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Eldar-Finkelman; Hagit	Shoham			IL

US-CL-CURRENT: 435/194; 435/15, 514/7, 530/324, 530/325, 530/326, 530/327, 530/328, 530/329

ABSTRACT:

Peptide inhibitors of glycogen synthase kinase-3 (GSK-3) have an amino acid sequence motif of XZXXXS(p)X, wherein S(p)=phosphorylated serine or phosphorylated threonine, X=any amino acid, and Z=any amino acid except serine or threonine. These inhibitors, which are about 7 to 50 amino acids long, are specific for GSK-3 and strongly inhibit the enzyme with an IC.sub.50 of about 150 .mu.M. Also provided are methods of treating biological conditions mediated by GSK-3 activity, such as potentiating insulin signaling in a subject, treating or preventing type 2 diabetes in a patient, and treating Alzheimer's Disease by administering peptide inhibitors. Compositions of these peptide inhibitors and pharmaceutically acceptable carriers are also provided, as is a method for identifying inhibitors of GSK-3. The invention further relates to a computer-assisted method of structure based drug design of GSK-3 inhibitors using a three-dimensional structure of a peptide substrate of GSK-3.

13 Claims, 11 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 7

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 5. Document ID: US 6692916 B2

L6: Entry 5 of 34 File: USPT Feb 17, 2004

US-PAT-NO: 6692916
DOCUMENT-IDENTIFIER: US 6692916 B2
**** See image for Certificate of Correction ****

TITLE: Systems and methods for characterizing a biological condition or agent using precision gene expression profiles

DATE-ISSUED: February 17, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bevilacqua; Michael P.	Boulder	CO		
Bankaitis-Davis; Danute M.	Longmont	CO		
Cheronis; John C.	Conifer	CO		
Tryon; Victor	Loveland	CO		

US-CL-CURRENT: 435/6; 702/19, 702/20

ABSTRACT:

Methods are provided for evaluating a biological condition of a subject using a calibrated profile data set derived from a data set having a plurality of members, each member being a quantitative measure of the amount of a subject's RNA or protein as distinct constituents in a panel of constituents. The biological condition may be a naturally occurring physiological state or may be responsive to treatment of the subject with one or more agents. Calibrated profile data sets may be used as a descriptive record for an agent.

17 Claims, 59 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 49

☐ 6. Document ID: US 6673908 B1

L6: Entry 6 of 34 File: USPT Jan 6, 2004

US-PAT-NO: 6673908
DOCUMENT-IDENTIFIER: US 6673908 B1

TITLE: Tumor necrosis factor receptor 2

DATE-ISSUED: January 6, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Stanton, Jr.; Vincent P.	Belmont	MA		

US-CL-CURRENT: 536/22.1; 435/6, 435/91.1, 435/91.2, 536/23.1, 536/24.3, 536/24.31, 536/24.33

ABSTRACT:

The present disclosure describes the use of genetic variance information for genes involved in inflammatory or immunologic disease, disorder, or dysfunction. The

variance information is indicative of the expected response of a patient to a method of treatment. Methods of determining relevant variance information and additional methods of using such variance information are also described.

10 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 7. Document ID: US 6664089 B2

L6: Entry 7 of 34 File: USPT Dec 16, 2003

US-PAT-NO: 6664089
DOCUMENT-IDENTIFIER: US 6664089 B2

TITLE: 38692 and 21117, novel dual specificity phosphatase molecules and uses therefor

DATE-ISSUED: December 16, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Meyers; Rachel A.	Newton	MA		

US-CL-CURRENT: 435/196; 435/252.3, 435/320.1, 435/71.1, 536/23.2

ABSTRACT:

The invention provides isolated nucleic acids molecules, designated 38692 or 21117 nucleic acid molecules, which encode novel dual specificity phosphatase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 38692 or 21117 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 38692 or 21117 gene has been introduced or disrupted. The invention still further provides isolated 38692 or 21117 proteins, fusion proteins, antigenic peptides and anti-38692 or 21117 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

6 Claims, 19 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 16

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 8. Document ID: US 6632934 B1

L6: Entry 8 of 34 File: USPT Oct 14, 2003

US-PAT-NO: 6632934
DOCUMENT-IDENTIFIER: US 6632934 B1

TITLE: MORC gene compositions and methods of use

DATE-ISSUED: October 14, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Moreadith; Randall W.	Chapel Hill	NC		
Zinn; Andrew R.	Dallas	TX		
Watson; Mark L.	Dallas	TX		
Inoue; Norimitsu	Yao			JP
Hess; Karl D.	McDade	TX		
Albright; George M.	Irving	TX		

US-CL-CURRENT: 536/23.1

ABSTRACT:

Disclosed are compositions and methods comprising a novel mammalian gene, designated MORC, that is expressed in male germ cells. Also disclosed are polynucleotide compositions comprising a MORC gene from human and murine sources, and polypeptides encoded by these nucleic acid sequences. Methods for preparing MORC polypeptides, transformed host cells, and antibodies reactive with MORC polypeptides are also provided. In certain embodiments, the invention describes methods for diagnosing and treating infertility or testicular cancer, as well as methods for identifying MORC-related polynucleotide and polypeptide compositions.

2 Claims, 27 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 8

☐ 9. Document ID: US 6627735 B2

L6: Entry 9 of 34 File: USPT Sep 30, 2003

US-PAT-NO: 6627735
DOCUMENT-IDENTIFIER: US 6627735 B2

TITLE: Islet cell antigen 1851

DATE-ISSUED: September 30, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Kindsvogel; Wayne	Seattle	WA		
Jelinek; Laura J.	Seattle	WA		
Sheppard; Paul O.	Redmond	WA		
Hagopian; William A.	Seattle	WA		
LaGasse; James M.	Seattle	WA		

US-CL-CURRENT: 530/350; 424/185.1

ABSTRACT:

A mammalian islet cell antigen polypeptide involved in the development of insulin-dependent diabetes mellitus (IDDM) is disclosed. This islet cell antigen polypeptide, 1851, was found to contain regions of homology to the protein tyrosine phosphatase family. Methods for diagnosis and treatment, including use in immunoprecipitation assays and the induction of immune tolerance using the recombinant mammalian polypeptides and antibodies specific to mammalian islet cell antigen 1851 polypeptides are presented.

3 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWMC | Draw D

☐ 10. Document ID: US 6541615 B1

L6: Entry 10 of 34 File: USPT Apr 1, 2003

US-PAT-NO: 6541615
DOCUMENT-IDENTIFIER: US 6541615 B1

TITLE: SIRP proteins and uses thereof

DATE-ISSUED: April 1, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ullrich; Axel	Munchen			DE
Kharitonenkov; Alexei	Carmel	IN		
Chen; Zhengiun	Graefelfing			DE

US-CL-CURRENT: 536/23.1; 435/320.1, 435/325, 435/455, 435/6, 435/7.1, 530/300, 530/350, 536/23.6, 800/8

ABSTRACT:

The present invention features isolated, purified, or enriched nucleic acid encoding a SIRP polypeptide and isolated, purified, or enriched SIRP polypeptide and uses thereof.

17 Claims, 3 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 3

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWMC | Draw D

☐ 11. Document ID: US 6500937 B1

L6: Entry 11 of 34 File: USPT Dec 31, 2002

US-PAT-NO: 6500937
DOCUMENT-IDENTIFIER: US 6500937 B1

TITLE: Nucleotide sequence encoding a mammary cell growth inhibitor

DATE-ISSUED: December 31, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ervin, Jr.; Paul R.	Ann Arbor	MI		

US-CL-CURRENT: 536/23.1; 435/320.1, 436/64

ABSTRACT:

A nucleic acid sequence encoding Mammastatin, a specific mammary cell growth inhibitor. Mammastatin is encoded by a single nucleic acid sequence and has an approximate molecular weight of 44 kDa in its inactive, non-phosphorylated form. Normal mammary cells express functional phosphorylated forms having approximate molecular weights of 53 kDa and 49 kDa. Metastatic mammary cells either do not express Mammastatin at all, or do not express the 53 kDa or 49 kDa, phosphorylated forms. Mammary cancer cells are inhibited in their growth by the administration of phosphorylated mammastatin.

3 Claims, 21 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 18

☐ 12. Document ID: US 6482605 B1

L6: Entry 12 of 34 File: USPT Nov 19, 2002

US-PAT-NO: 6482605
DOCUMENT-IDENTIFIER: US 6482605 B1
**** See image for Certificate of Correction ****

TITLE: Protein tyrosine phosphatase PTP20 and related products and methods

DATE-ISSUED: November 19, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Aoki; Naohito	Nagoya			JP
Ullrich; Axel	Martimiried			DE

US-CL-CURRENT: 435/21; 435/194, 435/252.3, 435/320.1, 530/350, 536/23.2

ABSTRACT:

The present invention relates to a novel polypeptide, PTP20, and to nucleic acid molecules encoding the polypeptide . The invention also relates to nucleic acid molecules encoding portions of the phosphatase, nucleic acid vectors containing PTP20 related nucleic acid molecules, recombinant cells containing such nucleic acid vectors, polypeptides purified from such recombinant cells, antibodies to such polypeptides, and methods of identifying compounds that bind PTP20 or abrogate its interactions with natural binding partners. Also disclosed are methods for diagnosing abnormal conditions in an organism with PTP20 related molecules or compounds.

11 Claims, 0 Drawing figures
Exemplary Claim Number: 1

☐ 13. Document ID: US 6455026 B1

L6: Entry 13 of 34 File: USPT Sep 24, 2002

US-PAT-NO: 6455026
DOCUMENT-IDENTIFIER: US 6455026 B1

TITLE: Use of protein tyrosine phosphatase zeta as a biomolecular target in the treatment and visualization of brain tumors

DATE-ISSUED: September 24, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Mueller; Sabine	San Francisco	CA		
Melcher; Thorsten	San Francisco	CA		
Chin; Daniel J.	Foster City	CA		

US-CL-CURRENT: 424/1.49; 424/1.11, 424/1.65, 424/9.1, 435/21

ABSTRACT:

The present invention relates to the use of proteins which are differentially expressed in primary brain tumor tissues, as compared to normal brain tissues, as biomolecular targets for brain tumor treatment therapies. Specifically, the present invention relates to the use of immunotherapeutic and immunoimaging agents that specifically bind to human protein tyrosine phosphatase-zeta (PTP.zeta.) for the treatment and visualization of brain tumors in patients. The present invention also provides compounds and pharmaceutically acceptable compositions for administration in the methods of the invention.

63 Claims, 1 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 1

☐ 14. Document ID: US 6451765 B1

L6: Entry 14 of 34 File: USPT Sep 17, 2002

US-PAT-NO: 6451765
DOCUMENT-IDENTIFIER: US 6451765 B1
** See image for Certificate of Correction **

TITLE: Methods for treating breast cancer using Mammastatin

DATE-ISSUED: September 17, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ervin, Jr.; Paul R.	Ann Arbor	MI		

US-CL-CURRENT: 514/21; 424/184.1, 424/198.1, 436/64, 514/2, 514/7

ABSTRACT:

A nucleic acid sequence encoding Mammastatin, a specific mammary cell growth inhibitor. Mammastatin is encoded by a single nucleic acid sequence and has an approximate molecular weight of 44 kDa in its inactive, non-phosphorylated form. Normal mammary cells express functional phosphorylated forms having approximate molecular weights of 53 kDa and 49 kDa. Metastatic mammary cells either do not express Mammastatin at all, or do not express the 53 kDa or 49 kDa, phosphorylated forms. Mammary cancer cells are inhibited in their growth by the administration of phosphorylated Mammastatin.

18 Claims, 21 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 18

☐ 15. Document ID: US 6420153 B1

L6: Entry 15 of 34 File: USPT Jul 16, 2002

US-PAT-NO: 6420153
DOCUMENT-IDENTIFIER: US 6420153 B1

TITLE: 18232, a novel dual specificity phosphatase and uses therefor

DATE-ISSUED: July 16, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Meyers; Rachel A.	Newton	MA		
Weich; Nadine	Brookline	MA		

US-CL-CURRENT: 435/196; 435/252.3, 435/320.1, 435/325, 536/23.1, 536/23.2, 536/24.1

ABSTRACT:

The invention provides isolated nucleic acids molecules, designated 18232 nucleic acid molecules, which encode novel dual specificity phosphatase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 18232 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 18232 gene has been introduced or disrupted. The invention still further provides isolated 18232 proteins, fusion proteins, antigenic peptides and anti-18232 antibodies. Diagnostic methods utilizing compositions of the invention are also provided. The invention also provides methods of modulating the differentiation and proliferation of hematopoietic cells (e.g., erythroid cells) utilizing the compositions of the invention. Accordingly, methods of treating, preventing and/or diagnosing erythroid-associated disorders such as anemias, leukemias, and erythrocytosis are disclosed.

15 Claims, 9 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 8

☐ 16. Document ID: US 6388076 B1

L6: Entry 16 of 34 File: USPT May 14, 2002

US-PAT-NO: 6388076
DOCUMENT-IDENTIFIER: US 6388076 B1

TITLE: Protein tyrosine phosphatase-inhibiting compounds

DATE-ISSUED: May 14, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Mjalli; Adnan	Econdido	CA		
Sarshar; Sepehr	Cardiff by the Sea	CA		
Cao; Xiaodong	Carlsbad	CA		
Bakir; Farid	San Diego	CA		

US-CL-CURRENT: 544/350

ABSTRACT:

Y--X--C(R').dbd.C(R")COOR'" (A1)

The present invention relates to novel protein tyrosine phosphatase modulating compounds having the general structure shown in Formula (A1), to methods for their preparation, to compositions comprising the compounds, to their use for treatment of human and animal disorders, to their use for purification of proteins or glycoproteins, and to their use in diagnosis. The invention relates to modulation

of the activity of molecules with phosphotyrosine recognition units, including protein tyrosine phosphatases (PTPases) and proteins with Src-homology-2 domains, in in vitro systems, microorganisms, eukaryoic cells, whole animals and human beings. R' and R" are independently selected from the group consisting of hydrogen, halo, cyano, nitro, trihalomethyl, alkyl, arylalkyl. R'" is selected from the group consisting of hydrogen, alkyl, substituted alkyl, aryl, arylalkyl, X is aryl, Y is selected from hydrogen or ##STR1##

wherein (*) indicates a potential point of attachment to X.

16 Claims, 0 Drawing figures
Exemplary Claim Number: 1

☐ 17. Document ID: US 6372744 B1

L6: Entry 17 of 34 File: USPT Apr 16, 2002

US-PAT-NO: 6372744
DOCUMENT-IDENTIFIER: US 6372744 B1
**** See image for Certificate of Correction ****

TITLE: .beta.-sheet mimetics and methods relating to the use thereof

DATE-ISSUED: April 16, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Qabar; Maher N.	Redmond	WA		
McMillan; Michael K.	Bellevue	WA		
Kahn; Michael S.	Kirkland	WA		
Tulinsky; John E.	Seattle	WA		
Ogbu; Cyprian O.	Bellevue	WA		
Mathew; Jessymol	Bellevue	WA		

US-CL-CURRENT: 514/248; 514/384, 530/323, 530/332, 548/263.4

ABSTRACT:

.beta.-sheet mimetics and methods relating to the same are disclosed. The .beta.-sheet mimetics have utility as protease and kinase inhibitors, as well as inhibitors of transcription factors and protein-protein binding interactions. Methods of the invention include administration of a .beta.-sheet mimetic, or use of the same for the manufacture of a medicament for treatment of a variety of conditions associated with the targeted protease, kinase, transcription factor and/or protein-protein binding interaction.

73 Claims, 7 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 6

☐ 18. Document ID: US 6300093 B1

L6: Entry 18 of 34 File: USPT Oct 9, 2001

US-PAT-NO: 6300093
DOCUMENT-IDENTIFIER: US 6300093 B1

TITLE: Islet cell antigen 1851

DATE-ISSUED: October 9, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Kindsvogel; Wayne	Seattle	WA		
Jelinek; Laura J.	Seattle	WA		
Sheppard; Paul O.	Redmond	WA		
Hagopian; William A.	Seattle	WA		
LaGasse; James M.	Seattle	WA		

US-CL-CURRENT: 435/69.1; 435/252.3, 435/252.33, 435/254.11, 435/320.1, 435/325, 530/324, 530/350, 536/23.5

ABSTRACT:

A mammalian islet cell antigen polypeptide involved in the development of insulin-dependent diabetes mellitus (IDDM) is disclosed. This islet cell antigen polypeptide, 1851, was found to contain regions of homology to the protein tyrosine phosphatase family. Methods for diagnosis and treatment, including use in immunoprecipitation assays and the induction of immune tolerance using the recombinant mammalian polypeptides and antibodies specific to mammalian islet cell antigen 1851 polypeptides are presented.

6 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 19. Document ID: US 6238902 B1

L6: Entry 19 of 34 File: USPT May 29, 2001

US-PAT-NO: 6238902
DOCUMENT-IDENTIFIER: US 6238902 B1

TITLE: Protein tyrosine phosphatases

DATE-ISSUED: May 29, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Cheng; Jill	Burlingame	CA		
Lasky; Laurence A.	Sausalito	CA		

US-CL-CURRENT: 435/196; 435/325, 435/377

ABSTRACT:

This invention concerns new non-receptor protein tyrosine phosphatases of the hematopoietic stem cells (PTP HSC). The invention specifically concerns native murine and human PTP HSCs, their analogs in other mammals, and their functional derivatives. The invention further relates to nucleic acid encoding these proteins, vectors containing and capable of expressing such nucleic acid, and recombinant host cells transformed with such nucleic acid. Assays for identifying agonists and antagonists of the native PTP HSCs, methods for expansion of undifferentiated stem cells, and methods for the induction of stem cell differentiation are also within the scope of the invention.

3 Claims, 15 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 10

☐ 20. Document ID: US 6214564 B1

L6: Entry 20 of 34 File: USPT Apr 10, 2001

US-PAT-NO: 6214564
DOCUMENT-IDENTIFIER: US 6214564 B1

TITLE: Method of identifying modulators of protein tyrosine phosphatase activity

DATE-ISSUED: April 10, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Rodan; Gideon A.	Bryn Mawr	PA		
Rutledge; Su Jane	East Greenville	PA		
Schmidt; Azriel	Bryn Mawr	PA		

US-CL-CURRENT: 435/7.1; 435/252.3, 435/320.1, 435/325, 435/471, 435/69.1, 435/7.2, 435/70.1, 435/71.1, 435/71.2, 530/350 , 536/23.2

ABSTRACT:

A human protein tyrosine phosphatase (PTP) has been identified and its cDNA has been isolated. This PTP, denoted PTP-OB, has a receptor-like three dimensional structure and is present in osteoblasts. PTP-OB is involved in osteoblast differentiation, and modulators of PTP-OB activity in turn modulate osteoblast differentiation, osteoclast differentiation and osteoclast activity.

6 Claims, 12 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 12

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 21. Document ID: US 6156732 A

L6: Entry 21 of 34 File: USPT Dec 5, 2000

US-PAT-NO: 6156732
DOCUMENT-IDENTIFIER: US 6156732 A

TITLE: Azole peptidomimetics as thrombin receptor antagonists

DATE-ISSUED: December 5, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hoekstra; William	Villanova	PA		
Hulshizer; Becky L.	North Wales	PA		

US-CL-CURRENT: 514/18; 514/17, 514/2, 514/822

ABSTRACT:

Azole derivatives of formula (I): ##STR1## are disclosed as useful in treating platelet-mediated thrombotic disorders.

2 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 22. Document ID: US 6143879 A

L6: Entry 22 of 34 File: USPT Nov 7, 2000

US-PAT-NO: 6143879
DOCUMENT-IDENTIFIER: US 6143879 A
** See image for Certificate of Correction **

TITLE: Nucleotide cleaving agents and method

DATE-ISSUED: November 7, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Que, Jr.; Lawrence	Roseville	MN		

Hanson; Richard S.	Falcon Heights	MN
Schnaith; Leah M. T.	Redwing	MN

US-CL-CURRENT: 536/23.1; 536/124, 536/24.3, 536/25.3

ABSTRACT:

The present invention provides a unique series of nucleotide cleaving agents and a method for cleaving a nucleotide sequence, whether single-stranded or double-stranded DNA or RNA, using and a cationic metal complex having at least one polydentate ligand to cleave the nucleotide sequence phosphate backbone to yield a hydroxyl end and a phosphate end.

28 Claims, 6 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw. D

☐ 23. Document ID: US 6117896 A

L6: Entry 23 of 34 File: USPT Sep 12, 2000

US-PAT-NO: 6117896
DOCUMENT-IDENTIFIER: US 6117896 A
**** See image for Certificate of Correction ****

TITLE: Methods for regulating transcription factors

DATE-ISSUED: September 12, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Qabar; Maher N.	Redmond	WA		
McMillan; Michael K.	Bellevue	WA		
Kahn; Michael S.	Kirkland	WA		
Tulinsky; John E.	Seattle	WA		
Ogbu; Cyprian O.	Bellevue	WA		
Mathew; Jessymol	Bellevue	WA		

US-CL-CURRENT: 514/384; 514/248, 530/323, 530/332, 548/263.4

ABSTRACT:

.beta.-sheet mimetics and methods relating to the same are disclosed. The .beta.-sheet mimetics have utility as protease and kinase inhibitors, as well as inhibitors of transcription factors and protein-protein binding interactions. Methods of the invention include administration of a .beta.-sheet mimetic, or use of the same for the manufacture of a medicament for treatment of a variety of conditions associated with the targeted protease, kinase, transcription factor and/or protein-protein binding interaction.

34 Claims, 7 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 6

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 24. Document ID: US 6074851 A

L6: Entry 24 of 34 File: USPT Jun 13, 2000

US-PAT-NO: 6074851
DOCUMENT-IDENTIFIER: US 6074851 A

TITLE: Catalytic macro molecules having cdc25B like activity

DATE-ISSUED: June 13, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Deibel, Jr.; Martin R.	Kalamazoo	MI		
Yem; Anthony W.	Kalamazoo	MI		
Wolfe; Cindy L.	Portage	MI		

US-CL-CURRENT: 435/69.7; 435/194

ABSTRACT:

This invention discloses novel forms of catalytic macro molecules that are related to cdc25B, a cell cycle specific phosphatase. These special domains of cdc25B, special fusions with GST, and unique peptides and proteins, their utility, and the method of making them are all described.

3 Claims, 6 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 9

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 25. Document ID: US 6060481 A

L6: Entry 25 of 34 File: USPT May 9, 2000

US-PAT-NO: 6060481
DOCUMENT-IDENTIFIER: US 6060481 A

TITLE: Method for improving insulin sensitivity using an adenosine receptor antagonist

DATE-ISSUED: May 9, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
LaNoue; Kathryn F.	Hershey	PA		
Crist; George H.	Harrisburg	PA		
Linden; Joel M.	Charlottesville	VA		

US-CL-CURRENT: 514/263.34; 514/263.24

ABSTRACT:

Methods for improving insulin sensitivity in a patient using one or more A.sub.2B adenosine receptor antagonists are disclosed. These methods stimulate insulin dependent glucose uptake in muscle.

15 Claims, 10 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 10

☐ 26. Document ID: US 5951979 A

L6: Entry 26 of 34 File: USPT Sep 14, 1999

US-PAT-NO: 5951979
DOCUMENT-IDENTIFIER: US 5951979 A

TITLE: Substrate trapping protein tyrosine phosphatases

DATE-ISSUED: September 14, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Tonks; Nicholas	Huntington	NY		
Flint; Andrew J.	Bothell	WA		

US-CL-CURRENT: 424/94.6; 435/196

ABSTRACT:

Novel protein tyrosine phosphatases in which the invariant aspartate residue is replaced with an alanine residue and which bind to a tyrosine phosphorylated substrate and are catalytically attenuated are described. Also described are methods of identifying tyrosine phosphorylated proteins which complex with the described protein tyrosine phosphatases.

8 Claims, 2 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 6

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 27. Document ID: US 5912138 A

L6: Entry 27 of 34 File: USPT Jun 15, 1999

US-PAT-NO: 5912138
DOCUMENT-IDENTIFIER: US 5912138 A

TITLE: Substrate trapping protein tyrosine phosphatases

DATE-ISSUED: June 15, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Tonks; Nicholas	Huntington	NY		
Flint; Andrew J.	Bothell	WA		

US-CL-CURRENT: 435/21; 435/196

ABSTRACT:

Novel protein tyrosine phosphatases in which the invariant aspartate residue is replaced with an alanine residue and which bind to a tyrosine phosphorylated substrate and are catalytically attenuated are described. Also described are methods of identifying tyrosine phosphorylated proteins which complex with the described protein tyrosine phosphatases.

21 Claims, 2 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 6

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 28. Document ID: US 5866397 A

L6: Entry 28 of 34 File: USPT Feb 2, 1999

US-PAT-NO: 5866397
DOCUMENT-IDENTIFIER: US 5866397 A

TITLE: Human protein tyrosine phosphatase OB protein

DATE-ISSUED: February 2, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Rodan; Gideon A.	Bryn Mawr	PA		
Rutledge; Su Jane	East Greenville	PA		
Schmidt; Azriel	Bryn Mawr	PA		

US-CL-CURRENT: 435/196; 435/69.1, 530/350

ABSTRACT:

A novel human protein tyrosine phosphatase (PTP) has been identified and its cDNA has been isolated. This novel PTP, denoted PTP-OB, has a receptor-like three dimensional structure and is present in osteoblasts. PTP-OB is involved in osteoblast differentiation, and modulators of PTP-OB activity in turn modulate osteoblast differentiation, osteoclast differentiation and osteoclast activity.

7 Claims, 20 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 12

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 29. Document ID: US 5770620 A

L6: Entry 29 of 34 File: USPT Jun 23, 1998

US-PAT-NO: 5770620
DOCUMENT-IDENTIFIER: US 5770620 A

TITLE: Aryl acrylic acid derivatives useful as protein tyrosine phosphatase inhibitors

DATE-ISSUED: June 23, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Mjalli; Adnan M. M.	Vista	CA		
Cao; Xiaodong	Carlsbad	CA		
Moran; Edmund J.	Cardiff	CA		

US-CL-CURRENT: 514/415; 514/466, 514/471, 514/506, 514/563, 548/495, 549/441, 549/450, 560/42, 562/448

ABSTRACT:

The present invention provides novel protein tyrosine phosphatase modulating compounds having an aryl acrylic acid structure, compositions comprising the compounds, and methods of making and using the same.

27 Claims, 5 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 30. Document ID: US 5688992 A

L6: Entry 30 of 34 File: USPT Nov 18, 1997

US-PAT-NO: 5688992
DOCUMENT-IDENTIFIER: US 5688992 A

TITLE: O-malonyltryrosyl compounds, O-malonyltryrosyl compound-containing peptides, and use thereof

DATE-ISSUED: November 18, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Burke, Jr.; Terrence R.	Bethesda	MD		
Ye; Bin	Gaithersburg	MD		
Akamatsu; Miki	Rockville	MD		
Kole; Hemanta K.	Baltimore	MD		
Yan; Xinjian	Rockville	MD		
Roller; Peter R.	Rockville	MD		

US-CL-CURRENT: 560/82; 560/76, 562/65

ABSTRACT:

The present invention relates to non-phosphorus containing O-malonyltryrosyl compounds, derivatives thereof, uses of the O-malonyltryrosyl compounds in the synthesis of peptides, and O-malonyltryrosyl compound-containing peptides. The O-malonyltyrosyl malonyltyrosyl compounds and O-malonyltryrosyl compound-containing peptides of the present invention are uniquely stable to phosphotases, capable of crossing cell membranes, suitable for application to peptide synthesis of O-malonyltryrosyl compound-containing peptides, and amenable to prodrag defivatization for delivery into cells. The present invention also provides for O-malonyltryrosyl compound-containing peptides which exhibit inhibitory potency against binding interactions of receptor domains with phosphotyrosyl-containing peptide ligands.

11 Claims, 4 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 3

Terms	Documents
(HPTP or protein adj3 tyrosine phosphatase) same (crystal or x-ray)	34

Display Format: - Change Format

Previous Page Next Page Go to Doc#

Hit List

First Hit | Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Search Results - Record(s) 1 through 30 of 44 returned.

☐ 1. Document ID: US 20060069066 A1

Using default format because multiple data bases are involved.

L7: Entry 1 of 44 File: PGPB Mar 30, 2006

PGPUB-DOCUMENT-NUMBER: 20060069066
PGPUB-FILING-TYPE:
DOCUMENT-IDENTIFIER: US 20060069066 A1

TITLE: Glycogen synthase kinase-3 inhibitors

PUBLICATION-DATE: March 30, 2006

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Eldar-Finkelman; Hagit	Shoham		IL
Portnoy; Moshe	Givat Shmuel		IL

US-CL-CURRENT: 514/80; 546/22, 548/113

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 2. Document ID: US 20060046259 A1

L7: Entry 2 of 44 File: PGPB Mar 2, 2006

PGPUB-DOCUMENT-NUMBER: 20060046259
PGPUB-FILING-TYPE:
DOCUMENT-IDENTIFIER: US 20060046259 A1

TITLE: Differential expression of molecules associated with acute stroke

PUBLICATION-DATE: March 2, 2006

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Baird; Alison E.	Bethesda	MD	US
Moore; David F.	Rockville	MD	US
Goldin; Ehud	Rockville	MD	US

US-CL-CURRENT: 435/6; 436/86

☐ 3. Document ID: US 20060046249 A1

L7: Entry 3 of 44 File: PGPB Mar 2, 2006

PGPUB-DOCUMENT-NUMBER: 20060046249
PGPUB-FILING-TYPE:
DOCUMENT-IDENTIFIER: US 20060046249 A1

TITLE: Identification of polynucleotides and polypetide for predicting activity of compounds that interact with protein tyrosine kinase and or protein tyrosine kinase pathways

PUBLICATION-DATE: March 2, 2006

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Huang; Fei	Princeton	NJ	US
Fairchild; CraigR	Yardley	PA	US
Lee; FrancisY	Yardley	PA	US
Shaw; Peter	Yardley	PA	US

US-CL-CURRENT: 435/6; 536/24.1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 4. Document ID: US 20060045853 A1

L7: Entry 4 of 44 File: PGPB Mar 2, 2006

PGPUB-DOCUMENT-NUMBER: 20060045853
PGPUB-FILING-TYPE:
DOCUMENT-IDENTIFIER: US 20060045853 A1

TITLE: Cross-beta structure comprising amyloid-binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fibril formation and for modulating cross-beta structure-mediated toxicity

PUBLICATION-DATE: March 2, 2006

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Kroon-Batenburg; Louise Maria Johanna	Eemnes		NL
Bouma; Barend	Houten		NL
Kranenburg; Onno Wouter	Amsterdam		NL
Gebbink; Martijn Frans Ben Gerard	Bunnik		NL

US-CL-CURRENT: 424/50; 424/94.64, 435/7.1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 5. Document ID: US 20060030544 A1

L7: Entry 5 of 44 File: PGPB Feb 9, 2006

PGPUB-DOCUMENT-NUMBER: 20060030544
PGPUB-FILING-TYPE:
DOCUMENT-IDENTIFIER: US 20060030544 A1

TITLE: Protein kinase and phosphatase inhibitors and methods for designing them

PUBLICATION-DATE: February 9, 2006

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Hangauer; David G. JR.	Amherst	NY	US
El-Araby; Moustafa E.	Plainsboro	NJ	US
Milkiewicz; Karen L.	Exton	PA	US

US-CL-CURRENT: 514/80; 514/419, 548/414, 548/493

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 6. Document ID: US 20060025361 A1

L7: Entry 6 of 44 File: PGPB Feb 2, 2006

PGPUB-DOCUMENT-NUMBER: 20060025361
PGPUB-FILING-TYPE:
DOCUMENT-IDENTIFIER: US 20060025361 A1

TITLE: RNA interference mediated inhibition of protein tyrosine phosphatase-1B (PTP-1B) gene expression using short interfering nucleic acid (siNA)

PUBLICATION-DATE: February 2, 2006

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
McSwiggen; James	Boulder	CO	US
Beigelman; Leonid	Longmont	CO	US
Usman; Nassim	Lafayette	CO	US

US-CL-CURRENT: 514/44; 536/23.1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 7. Document ID: US 20060019913 A1

L7: Entry 7 of 44 File: PGPB Jan 26, 2006

PGPUB-DOCUMENT-NUMBER: 20060019913
PGPUB-FILING-TYPE:
DOCUMENT-IDENTIFIER: US 20060019913 A1

TITLE: RNA interference mediated inhibtion of protein tyrosine phosphatase-1B (PTP-1B) gene expression using short interfering nucleic acid (siNA)

PUBLICATION-DATE: January 26, 2006

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
McSwiggen; James	Boulder	CO	US
Beigelman; Leonid	Longmont	CO	US
Usman; Nassim	Lafayette	CO	US

US-CL-CURRENT: 514/44; 536/23.1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 8. Document ID: US 20060014180 A1

L7: Entry 8 of 44 File: PGPB Jan 19, 2006

PGPUB-DOCUMENT-NUMBER: 20060014180
PGPUB-FILING-TYPE:
DOCUMENT-IDENTIFIER: US 20060014180 A1

TITLE: Human phosphatase RET31, and variants thereof

PUBLICATION-DATE: January 19, 2006

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Jackson; Donald G.	Lawrenceville	NJ	US
Ramanathan; Chandra S.	Wallingford	CT	US
Feder; John N.	Belle Mead	NJ	US
Mintier; Gabe	Hightstown	NJ	US
Lee; Liana	North Brunswick	NJ	US
Nelson; Thomas C.	Lawrenceville	NJ	US
Siemers; Nathan	Pennington	NJ	US
Bol; David	Langhorne	PA	US
Suchard; Suzanne	Wilmington	DE	US
Schieven; Gary	Lawrenceville	NJ	US
Finger; Joshua	San Marcos	CA	US
Todderrud; C. Gordon	Newtown	PA	US
Bassolino; Donna	Hamilton	NJ	US
Krystek; Stanley	Ringoes	NJ	US
Banas; Dana	Hamilton	NJ	US

McAtee; Patrick Pennington NJ US

US-CL-CURRENT: 435/6; 435/320.1, 435/325, 435/69.1, 530/350, 536/23.5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 9. Document ID: US 20060003322 A1

L7: Entry 9 of 44 File: PGPB Jan 5, 2006

PGPUB-DOCUMENT-NUMBER: 20060003322
PGPUB-FILING-TYPE:
DOCUMENT-IDENTIFIER: US 20060003322 A1

TITLE: Bioinformatically detectable group of novel regulatory genes and uses thereof

PUBLICATION-DATE: January 5, 2006

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Bentwich; Isaac	Kvuzat Shiler		IL

US-CL-CURRENT: 435/6

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 10. Document ID: US 20050287535 A1

L7: Entry 10 of 44 File: PGPB Dec 29, 2005

PGPUB-DOCUMENT-NUMBER: 20050287535
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20050287535 A1

TITLE: Biomarkers for wound healing

PUBLICATION-DATE: December 29, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
McGrath, Kevin P.	Alpharetta	GA	US

US-CL-CURRENT: 435/6; 435/7.2

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 11. Document ID: US 20050237522 A1

L7: Entry 11 of 44 File: PGPB Oct 27, 2005

PGPUB-DOCUMENT-NUMBER: 20050237522
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20050237522 A1

TITLE: Methods for visualizing crystals and distinguishing crystals from other matter within a biological sample

PUBLICATION-DATE: October 27, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Swift, Kerry M.	Libertyville	IL	US
Matayoshi, Edmund D.	Richmond	IL	US

US-CL-CURRENT: 356/317; 250/461.1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 12. Document ID: US 20050186630 A1

L7: Entry 12 of 44 File: PGPB Aug 25, 2005

PGPUB-DOCUMENT-NUMBER: 20050186630
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20050186630 A1

TITLE: Extended tethering approach for rapid identification of ligands

PUBLICATION-DATE: August 25, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Erlanson, Daniel A.	San Francisco	CA	US
Braisted, Andrew C.	San Francisco	CA	US
McDowell, Robert	San Francisco	CA	US
Prescott, John	San Francisco	CA	US

US-CL-CURRENT: 435/6; 435/7.1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 13. Document ID: US 20050176101 A1

L7: Entry 13 of 44 File: PGPB Aug 11, 2005

PGPUB-DOCUMENT-NUMBER: 20050176101
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20050176101 A1

TITLE: Enzyme expression methods

PUBLICATION-DATE: August 11, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
West, Brian	San Francisco	CA	US

US-CL-CURRENT: 435/69.1; 435/194, 435/320.1, 435/325, 536/23.2

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 14. Document ID: US 20050147593 A1

L7: Entry 14 of 44 File: PGPB Jul 7, 2005

PGPUB-DOCUMENT-NUMBER: 20050147593
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20050147593 A1

TITLE: EphA2, EphA4 and LMW-PTP and methods of treatment of hyperproliferative cell disorders

PUBLICATION-DATE: July 7, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Kinch, Michael S.	Laytonsville	MD	US

US-CL-CURRENT: 424/93.2; 424/178.1, 424/450, 514/44

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 15. Document ID: US 20050142539 A1

L7: Entry 15 of 44 File: PGPB Jun 30, 2005

PGPUB-DOCUMENT-NUMBER: 20050142539
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20050142539 A1

TITLE: Targeted ligands

PUBLICATION-DATE: June 30, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Herman, William	Thornhill		CA

US-CL-CURRENT: 435/5; 435/7.23, 530/388.22, 530/388.3

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw De

☐ 16. Document ID: US 20050118164 A1

L7: Entry 16 of 44 File: PGPB Jun 2, 2005

PGPUB-DOCUMENT-NUMBER: 20050118164
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20050118164 A1

TITLE: Targeted ligands

PUBLICATION-DATE: June 2, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Herman, William	Thornhill		CA

US-CL-CURRENT: 424/133.1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw De

☐ 17. Document ID: US 20050070497 A1

L7: Entry 17 of 44 File: PGPB Mar 31, 2005

PGPUB-DOCUMENT-NUMBER: 20050070497
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20050070497 A1

TITLE: RNA interference mediated inhibtion of tyrosine phosphatase-1B (PTP-1B) gene expression using short interfering nucleic acid (siNA)

PUBLICATION-DATE: March 31, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
McSwiggen, James	Boulder	CO	US
Beigelman, Leonid	Longmont	CO	US
Usman, Nassim	Lafayette	CO	US

US-CL-CURRENT: 514/44; 435/375, 536/23.1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw De

☐ 18. Document ID: US 20050069549 A1

L7: Entry 18 of 44 File: PGPB Mar 31, 2005

PGPUB-DOCUMENT-NUMBER: 20050069549
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20050069549 A1

TITLE: Targeted ligands

PUBLICATION-DATE: March 31, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Herman, William	Thornhill		CA

US-CL-CURRENT: 424/178.1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 19. Document ID: US 20040225448 A1

L7: Entry 19 of 44 File: PGPB Nov 11, 2004

PGPUB-DOCUMENT-NUMBER: 20040225448
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040225448 A1

TITLE: Systems and methods for characterizing a biological condition or agent using selected gene expression profiles

PUBLICATION-DATE: November 11, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Bevilacqua, Michael P.	Boulder	CO	US
Bankaitis-Davis, Danute M.	Longmont	CO	US
Cheronis, John C.	Conifer	CO	US
Tryon, Victor	Loveland	CO	US

US-CL-CURRENT: 702/20

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 20. Document ID: US 20040225446 A1

L7: Entry 20 of 44 File: PGPB Nov 11, 2004

PGPUB-DOCUMENT-NUMBER: 20040225446
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040225446 A1

TITLE: Systems and methods for characterizing a biological condition or agent using selected gene expression profiles

PUBLICATION-DATE: November 11, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Bevilacqua, Michael P.	Boulder	CO	US
Bankaitis-Davis, Danute M.	Longmont	CO	US
Cheronis, John C.	Conifer	CO	US
Tryon, Victor	Loveland	CO	US

US-CL-CURRENT: 702/19

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 21. Document ID: US 20040225445 A1

L7: Entry 21 of 44 File: PGPB Nov 11, 2004

PGPUB-DOCUMENT-NUMBER: 20040225445
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040225445 A1

TITLE: Systems and methods for characterizing a biological condition or agent using selected gene expression profiles

PUBLICATION-DATE: November 11, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Bevilacqua, Michael P.	Boulder	CO	US
Bankaitis-Davis, Danute M.	Longmont	CO	US
Cheronis, John C.	Conifer	CO	US
Tryon, Victor	Loveland	CO	US

US-CL-CURRENT: 702/19

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 22. Document ID: US 20040224333 A1

L7: Entry 22 of 44 File: PGPB Nov 11, 2004

PGPUB-DOCUMENT-NUMBER: 20040224333
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040224333 A1

TITLE: Systems and methods for characterizing a biological condition or agent using selected gene expression profiles

PUBLICATION-DATE: November 11, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Bevilacqua, Michael P.	Boulder	CO	US
Cheronis, John C.	Conifer	CO	US
Tryon, Victor	Loveland	CO	US
Bankaitis-Davis, Danute M.	Longmont	CO	US

US-CL-CURRENT: 435/6; 702/20

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 23. Document ID: US 20040224322 A1

L7: Entry 23 of 44 File: PGPB Nov 11, 2004

PGPUB-DOCUMENT-NUMBER: 20040224322
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040224322 A1

TITLE: Systems and methods for characterizing a biological condition or agent using selected gene expression profiles

PUBLICATION-DATE: November 11, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Bevilacqua, Michael P.	Boulder	CO	US
Bankaitis-Davis, Danute M.	Longmont	CO	US
Cheronis, John C.	Conifer	CO	US
Tryon, Victor	Loveland	CO	US

US-CL-CURRENT: 435/6; 702/20

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 24. Document ID: US 20040219568 A1

L7: Entry 24 of 44 File: PGPB Nov 4, 2004

PGPUB-DOCUMENT-NUMBER: 20040219568
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040219568 A1

TITLE: Systems and methods for characterizing a biological conditions or agent using selected gene expression profiles

PUBLICATION-DATE: November 4, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY

Bevilacqua, Michael P.	Boulder	CO	US
Cheronis, John C.	Conifer	CO	US
Tryon, Victor	Loveland	CO	US
Bankaitis-Davis, Danute M.	Longmont	CO	US

US-CL-CURRENT: 435/6

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw. D

☐ 25. Document ID: US 20040157221 A9

L7: Entry 25 of 44 File: PGPB Aug 12, 2004

PGPUB-DOCUMENT-NUMBER: 20040157221
PGPUB-FILING-TYPE: corrected
DOCUMENT-IDENTIFIER: US 20040157221 A9

TITLE: Novel 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 and 49933 molecules and uses therefor

PUBLICATION-DATE: August 12, 2004

PRIOR-PUBLICATION:

DOC-ID	DATE
US 0009501 A1	January 15, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Curtis, Rory A. J.	Ashland	MA	US
Logan, Thomas Joseph	Springfield	PA	US
Glucksmann, Maria Alexandra	Lexington	MA	US
Meyers, Rachel E.	Newton	MA	US
Williamson, Mark J.	Saugus	MA	US
Rudolph-Owen, Laura A.	Medford	MA	US
Chun, Miyoung	Belmont	MA	US
Tsai, Fong-Ying	Newton	MA	US

US-CL-CURRENT: 435/6; 435/183, 435/320.1, 435/325, 435/69.1, 530/350, 536/23.2

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw. D

☐ 26. Document ID: US 20040077065 A1

L7: Entry 26 of 44 File: PGPB Apr 22, 2004

PGPUB-DOCUMENT-NUMBER: 20040077065
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040077065 A1

TITLE: Three dimensional coordinates of HPTPbeta

PUBLICATION-DATE: April 22, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Evdokimov, Artem Gennady	Loveland	OH	US
Pokross, Matthew Eugene	Loveland	OH	US

US-CL-CURRENT: 435/226; 702/19

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 27. Document ID: US 20040076955 A1

L7: Entry 27 of 44 File: PGPB Apr 22, 2004

PGPUB-DOCUMENT-NUMBER: 20040076955
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040076955 A1

TITLE: Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer

PUBLICATION-DATE: April 22, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Mack, David H.	Menlo Park	CA	US
Aziz, Natasha	Palo Alto	CA	US

US-CL-CURRENT: 435/6; 435/320.1, 435/325, 435/69.1, 530/350, 536/23.5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 28. Document ID: US 20040019001 A1

L7: Entry 28 of 44 File: PGPB Jan 29, 2004

PGPUB-DOCUMENT-NUMBER: 20040019001
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040019001 A1

TITLE: RNA interference mediated inhibition of protein tyrosine phosphatase-1B (PTP-1B) gene expression using short interfering RNA

PUBLICATION-DATE: January 29, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY

McSwiggen, James A. Boulder CO US

US-CL-CURRENT: 514/44; 435/375, 536/23.1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 29. Document ID: US 20040018513 A1

L7: Entry 29 of 44 File: PGPB Jan 29, 2004

PGPUB-DOCUMENT-NUMBER: 20040018513
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040018513 A1

TITLE: Classification and prognosis prediction of acute lymphoblastic leukemia by gene expression profiling

PUBLICATION-DATE: January 29, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Downing, James R.	Cordova	TN	US
Yeoh, Eng-Juh	Singapore	MS	SG
Wilkins, Dawn E.	Oxford		US
Wong, Limsoon	Singapore		SG

US-CL-CURRENT: 435/6

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 30. Document ID: US 20040009501 A1

L7: Entry 30 of 44 File: PGPB Jan 15, 2004

PGPUB-DOCUMENT-NUMBER: 20040009501
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040009501 A1

TITLE: Novel 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 and 49933 molecules and uses therefor

PUBLICATION-DATE: January 15, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Curtis, Rory A. J.	Ashland	MA	US
Logan, Thomas Joseph	Springfield	PA	US
Glucksmann, Maria Alexandra	Lexington	MA	US
Meyers, Rachel E.	Newton	MA	US
Williamson, Mark J.	Saugus	MA	US

Rudolph-Owen, Laura A.	Medford	MA	US
Chun, Miyoung	Belmont	MA	US
Tsai, Fong-Ying	Newton	MA	US

US-CL-CURRENT: 435/6; 435/183, 435/320.1, 435/325, 435/69.1, 530/350, 536/23.2

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw. D

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Terms	Documents
(HPTP or protein adj3 tyrosine phosphatase) same (crystal or x-ray)	44

Display Format: - Change Format

Previous Page Next Page Go to Doc#

Hit List

First Hit | Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Search Results - Record(s) 31 through 44 of 44 returned.

☐ 31. Document ID: US 20040005664 A1

Using default format because multiple data bases are involved.

L7: Entry 31 of 44 File: PGPB Jan 8, 2004

PGPUB-DOCUMENT-NUMBER: 20040005664
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040005664 A1

TITLE: Novel 26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 and 8843 molecules and uses therefor

PUBLICATION-DATE: January 8, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Meyers, Rachel E.	Newton	MA	US
MacBeth, Kyle J.	Boston	MA	US
Curtis, Rory A. J.	Ashland	MA	US
Rudolph-Owen, Laura A.	Medford	MA	US
Weich, Nadine S.	Brookline	MA	US
Olandt, Peter J.	Buffalo	NY	US
Tsai, Fong-Ying	Newton	MA	US
Kapeller-Libermann, Rosana	Chestnut Hill	MA	US
Carroll, Joseph M.	Cambridge	MA	US

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 435/6, 530/350, 530/388.22, 536/23.5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw. D

☐ 32. Document ID: US 20030235820 A1

L7: Entry 32 of 44 File: PGPB Dec 25, 2003

PGPUB-DOCUMENT-NUMBER: 20030235820
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030235820 A1

TITLE: Novel methods of diagnosis of metastatic colorectal cancer, compositions and methods of screening for modulators of metastatic colorectal cancer

PUBLICATION-DATE: December 25, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Mack, David H.	Menlo Park	CA	US
Markowitz, Sanford David	Pepper Pike	OH	US

US-CL-CURRENT: 435/6; 435/183, 435/320.1, 435/325, 435/69.1, 435/7.23, 530/388.26, 536/23.2

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 33. Document ID: US 20030229455 A1

L7: Entry 33 of 44 File: PGPB Dec 11, 2003

PGPUB-DOCUMENT-NUMBER: 20030229455
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030229455 A1

TITLE: SYSTEMS AND METHODS FOR CHARACTERIZING A BIOLOGICAL CONDITION OR AGENT USING PRECISION GENE EXPRESSION PROFILES

PUBLICATION-DATE: December 11, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Bevilacqua, Michael P.	Boulder	CO	US
Bankaitis-Davis, Danute M.	Longmont	CO	US
Cheronis, John C.	Conifer	CO	US
Tryon, Victor	Loveland	CO	US

US-CL-CURRENT: 702/20; 435/6

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 34. Document ID: US 20030224335 A1

L7: Entry 34 of 44 File: PGPB Dec 4, 2003

PGPUB-DOCUMENT-NUMBER: 20030224335
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030224335 A1

TITLE: Receptor linked protein tyrosine phosphatases

PUBLICATION-DATE: December 4, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Frederick, Christin	Newton	MA	US
Saito, Haruo	Newton	MA	US

US-CL-CURRENT: 434/193; 436/86

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 35. Document ID: US 20030166224 A1

L7: Entry 35 of 44 File: PGPB Sep 4, 2003

PGPUB-DOCUMENT-NUMBER: 20030166224
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030166224 A1

TITLE: 18232, a novel dual specificity phosphatase and uses therefor

PUBLICATION-DATE: September 4, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Meyers, Rachel A.	Newton	MA	US
Weich, Nadine	Brookline	MA	US

US-CL-CURRENT: 435/196; 435/320.1, 435/325, 435/69.1, 536/23.2

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 36. Document ID: US 20030166067 A1

L7: Entry 36 of 44 File: PGPB Sep 4, 2003

PGPUB-DOCUMENT-NUMBER: 20030166067
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030166067 A1

TITLE: Islet cell antigen 1851

PUBLICATION-DATE: September 4, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Kindsvogel, Wayne	Seattle	WA	US
Jelinek, Laura J.	Seattle	WA	US
Sheppard, Paul O.	Granite Falls	WA	US
Hagopian, William A.	Seattle	WA	US
LaGasse, James M.	Seattle	WA	US

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 435/326, 435/7.21, 530/350, 530/388.26, 536/23.5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 37. Document ID: US 20030158083 A1

L7: Entry 37 of 44 File: PGPB Aug 21, 2003

PGPUB-DOCUMENT-NUMBER: 20030158083
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030158083 A1

TITLE: Method of effecting angiogenesis by modulating the function of a novel endothelia phosphatase

PUBLICATION-DATE: August 21, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Peters, Kevin Gene	Loveland	OH	US

US-CL-CURRENT: 514/1; 424/94.6, 435/196, 435/320.1, 435/325, 435/7.23, 536/23.2

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw De

☐ 38. Document ID: US 20030054387 A1

L7: Entry 38 of 44 File: PGPB Mar 20, 2003

PGPUB-DOCUMENT-NUMBER: 20030054387
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030054387 A1

TITLE: Metastasis-associated genes

PUBLICATION-DATE: March 20, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Chen, Jeremy J.W.	Fengyuan City		TW
Yang, Pan-Chyr	Taipei		TW
Peck, Konan	Taipei		TW
Hong, Tse-Ming	Taipei		TW
Yang, Shuenn-Chen	Taipei		TW
Wu, Cheng-Wen	Taipei		TW

US-CL-CURRENT: 435/6; 702/20

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw De

☐ 39. Document ID: US 20030027819 A1

L7: Entry 39 of 44 File: PGPB Feb 6, 2003

PGPUB-DOCUMENT-NUMBER: 20030027819
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030027819 A1

TITLE: Beta-sheet mimetics and methods relating to the use thereof

PUBLICATION-DATE: February 6, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Qabar, Maher N.	Redmond	WA	US
McMillan, Michael K.	Bellevue	WA	US
Kahn, Michael S.	Kirkland	WA	US
Tulinsky, John E.	Seattle	WA	US
Ogbu, Cyprian O.	Bellevue	WA	US
Mathew, Jessymol	Bellevue	WA	US

US-CL-CURRENT: 514/224.2; 514/229.5, 514/299, 514/367, 514/373, 514/412, 514/434, 514/456, 514/469

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 40. Document ID: US 20020150947 A1

L7: Entry 40 of 44 File: PGPB Oct 17, 2002

PGPUB-DOCUMENT-NUMBER: 20020150947
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020150947 A1

TITLE: Extended tethering approach for rapid identification of ligands

PUBLICATION-DATE: October 17, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Erlanson, Daniel A.	San Francisco	CA	US
Braisted, Andrew C.	San Francisco	CA	US
McDowell, Robert	San Francisco	CA	US
Prescott, John	San Francisco	CA	US

US-CL-CURRENT: 435/7.1; 435/6, 436/518

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 41. Document ID: US 20020146370 A1

L7: Entry 41 of 44 File: PGPB Oct 10, 2002

PGPUB-DOCUMENT-NUMBER: 20020146370
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020146370 A1

TITLE: USE OF PROTEIN TYROSINE PHOSPHATASE ZETA AS A BIOMOLECULAR TARGET IN THE TREATMENT AND VISUALIZATION OF BRAIN TUMORS

PUBLICATION-DATE: October 10, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Mueller, Sabine	San Francisco	CA	US
Melcher, Thorsten	San Francisco	CA	US
Chin, Daniel J.	Foster City	CA	US

US-CL-CURRENT: 424/1.69

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 42. Document ID: US 20020102616 A1

L7: Entry 42 of 44 File: PGPB Aug 1, 2002

PGPUB-DOCUMENT-NUMBER: 20020102616
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020102616 A1

TITLE: Islet cell antigen 1851

PUBLICATION-DATE: August 1, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Kindsvogel, Wayne	Seattle	WA	US
Jelinek, Laura J.	Seattle	WA	US
Sheppard, Paul O.	Redmond	WA	US
Hagopian, William A.	Seattle	WA	US
LaGasse, James M.	Seattle	WA	US

US-CL-CURRENT: 435/7.9; 435/320.1, 435/326, 435/69.1, 530/387.2, 536/23.53

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 43. Document ID: US 20020065406 A1

L7: Entry 43 of 44 File: PGPB May 30, 2002

PGPUB-DOCUMENT-NUMBER: 20020065406
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020065406 A1

TITLE: 18221, a novel dual specificity phosphatase and uses thereof

PUBLICATION-DATE: May 30, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Meyers, Rachel A.	Newton	MA	US

US-CL-CURRENT: 536/23.1; 435/196, 435/6

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 44. Document ID: US 20020034807 A1

L7: Entry 44 of 44 File: PGPB Mar 21, 2002

PGPUB-DOCUMENT-NUMBER: 20020034807
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020034807 A1

TITLE: 38692 and 21117, novel dual specificity phosphatase molecules and uses therefor

PUBLICATION-DATE: March 21, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Meyers, Rachel A.	Newton	MA	US

US-CL-CURRENT: 435/196; 435/325, 435/6, 435/69.1, 435/7.1, 514/44, 530/388.1, 536/23.2

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Terms	Documents
(HPTP or protein adj3 tyrosine phosphatase) same (crystal or x-ray)	44

Display Format: - Change Format

Previous Page Next Page Go to Doc#

STN SEARCH **10634,027**

```
FILE 'HOME' ENTERED AT 17:05:47 ON 07 APR 2006
=> s hptpβ
L15          15 FILE MEDLINE
L16          19 FILE CAPLUS
L17          21 FILE SCISEARCH
L18          10 FILE LIFESCI
L19          13 FILE BIOSIS
L20          12 FILE EMBASE

TOTAL FOR ALL FILES
L21          90 HPTPB

=> s l21 and inhibitor
L22           1 FILE MEDLINE
L23           3 FILE CAPLUS
L24           5 FILE SCISEARCH
L25           0 FILE LIFESCI
L26           1 FILE BIOSIS
L27           2 FILE EMBASE

TOTAL FOR ALL FILES
L28          12 L21 AND INHIBITOR

=> dup rem l28
PROCESSING COMPLETED FOR L28
L29           8 DUP REM L28 (4 DUPLICATES REMOVED)

=> d 1-8 ibib abs

L29  ANSWER 1 OF 8  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:         2004:331682  CAPLUS Full-text
DOCUMENT NUMBER:          140:352651
TITLE:                    The three-dimensional structure of protein tyrosine
                          phosphatase β subunit and its use in drug design
INVENTOR(S):              Evdokimov, Artem Gennady; Pokross, Matthew Eugene
PATENT ASSIGNEE(S):       The Procter & Gamble Company, USA
SOURCE:                   U.S. Pat. Appl. Publ., 335 pp.
                          CODEN: USXXCO
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.          DATE
     ---------------      ----   --------    -------------------      --------
     US 2004077065         A1    20040422    US 2003-634027           20030804
PRIORITY APPLN. INFO.:                       US 2002-413547P      P   20020925
AB     The crystal structures of the catalytic domain of the human protein tyrosine phosphatase
       HPTPβ, in ligand-bound and ligand-free forms are described.  These structures are useful
       in computer aided drug design for identifying compds. that bind or activate HPTPbeta and
       thereby modulate angiogenesis mediated disorders or diseases.


L29  ANSWER 2 OF 8  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:         2003:580622  CAPLUS Full-text
DOCUMENT NUMBER:          140:87438
TITLE:                    Mechanism of insulin sensitization by BMOV (bis
                          maltolato oxo vanadium); unliganded vanadium (VO4) as
                          the active component
AUTHOR(S):                Peters, Kevin G.; Davis, Mike G.; Howard, Brian W.;
                          Pokross, Matthew; Rastogi, Vinit; Diven, Conrad;
                          Greis, Kenneth D.; Eby-Wilkens, Elaine; Maier,
                          Matthew; Evdokimov, Artem; Soper, Shari; Genbauffe,
                          Frank
CORPORATE SOURCE:         Cardiovascular Research, Procter & Gamble
                          Pharmaceuticals, Health Care Research Center, Mason,
                          OH, 45040, USA
SOURCE:                   Journal of Inorganic Biochemistry (2003), 96(2-3),
```

321-330
CODEN: JIBIDJ; ISSN: 0162-0134
PUBLISHER: Elsevier Science Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Organovanadium compds. have been shown to be insulin sensitizers in vitro and in vivo. One potential biochem. mechanism for insulin sensitization by these compds. is that they inhibit protein tyrosine phosphatases (PTPs) that neg. regulate insulin receptor activation and signaling. In this study, bismaltolato oxovanadium (BMOV), a potent insulin sensitizer, was shown to be a reversible, competitive phosphatase inhibitor that inhibited phosphatase activity in cultured cells and enhanced insulin receptor activation in vivo. NMR and x-ray crystallog. studies of the interaction of BMOV with two different phosphatases, HCPTPA (human low mol. weight cytoplasmic protein tyrosine phosphatase) and PTP1B (protein tyrosine phosphatase 1B), demonstrated uncomplexed vanadium (VO4) in the active site. Taken together, these findings support phosphatase inhibition as a mechanism for insulin sensitization by BMOV and other organovanadium compds. and strongly suggest that uncomplexed vanadium is the active component of these compds.
REFERENCE COUNT: 70 THERE ARE 70 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L29 ANSWER 3 OF 8 SCISEARCH COPYRIGHT (c) 2006 The Thomson Corporation on STN
ACCESSION NUMBER: 2001:452808 SCISEARCH Full-text
THE GENUINE ARTICLE: 434XQ
TITLE: Potent reversible inhibitors of the protein tyrosine phosphatase CD45
AUTHOR: Urbanek R A (Reprint); Suchard S J; Steelman G B; Knappenberger K S; Sygowski L A; Veale C A; Chapdelaine M J
CORPORATE SOURCE: AstraZeneca Pharmaceut, 1800 Concord Pike, Wilmington, DE 19850 USA (Reprint); AstraZeneca Pharmaceut, Wilmington, DE 19850 USA
COUNTRY OF AUTHOR: USA
SOURCE: JOURNAL OF MEDICINAL CHEMISTRY, (24 MAY 2001) Vol. 44, No. 11, pp. 1777-1793.
ISSN: 0022-2623.
PUBLISHER: AMER CHEMICAL SOC, 1155 16TH ST, NW, WASHINGTON, DC 20036 USA.
DOCUMENT TYPE: Article; Journal
LANGUAGE: English
REFERENCE COUNT: 66
ENTRY DATE: Entered STN: 15 Jun 2001
Last Updated on STN: 15 Jun 2001
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS
AB The cytosolic portion of CD45, a major transmembrane glycoprotein found on nucleated hematopoietic cells, contains protein tyrosine phosphatase activity and is critical for T-cell receptor-mediated T-cell activation. CD45 inhibitors could have utility in the treatment of autoimmune disorders and organ graft rejection. A number of 9, 10-phenanthrenediones were identified that reversibly inhibited CD45-mediated p-nitrophenyl phosphate (pNPP) hydrolysis. Chemistry efforts around the 9,10-phenanthrenedione core led to the most potent inhibitors known to date. In a functional assay, the compounds were also potent inhibitors of T-cell receptor-mediated proliferation, with activities in the low micromolar range paralleling their enzyme inhibition. It was also discovered that the nature of modification to the phenanthrenedione pharmacophore could affect selectivity for CD45 over PTP1B (protein tyrosine phosphatase 1B) or vice versa.

L29 ANSWER 4 OF 8 SCISEARCH COPYRIGHT (c) 2006 The Thomson Corporation on STN
ACCESSION NUMBER: 2000:810169 SCISEARCH Full-text
THE GENUINE ARTICLE: 368FQ
TITLE: Enzyme inhibition assays using fluorescence correlation spectroscopy: A new algorithm for the derivation of k(cat)/K-M and K-i values at substrate concentrations much lower than the Michaelis constant
AUTHOR: Meyer-Almes F J (Reprint); Auer M
CORPORATE SOURCE: EVOTEC Analyt Syst GmbH, Max Planck Str 15A, D-40699 Erkrath, Germany (Reprint); EVOTEC Analyt Syst GmbH, D-40699 Erkrath, Germany; Novartis Forschungsinst, A-1235 Vienna, Austria

COUNTRY OF AUTHOR: Germany; Austria
SOURCE: BIOCHEMISTRY, (31 OCT 2000) Vol. 39, No. 43, pp. 13261-13268.
ISSN: 0006-2960.
PUBLISHER: AMER CHEMICAL SOC, 1155 16TH ST, NW, WASHINGTON, DC 20036 USA.
DOCUMENT TYPE: Article; Journal
LANGUAGE: English
REFERENCE COUNT: 26
ENTRY DATE: Entered STN: 2000
Last Updated on STN: 2000
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

AB A new mathematical formalism is deduced which allows for the calculation of the k(cat) over K-M ratio based on measurements of the enzyme kinetics with substrate concentrations much lower than K-M. The equations are also applied on the action of an inhibitor on enzyme activity yielding the binding constant, K-i, of an inhibitor molecule. For practical evaluation of the new theoretical approach, the enzymatic reaction of CD45 phosphatase was used as a well-characterized model system with known inhibitors for testing the K-i value determination scheme. The k(cat)/K-M ratio was calulated to be 4.7 x 10(5) M-1 s(-1), the K-i of the inhibitor molecule PKF52-524 was estimated to be (1-2) x 10(-7) M and the association rate of the inhibitor PKF52-524 to CD45 phosphatase was estimated to be 59 M-1 s(-1).

L29 ANSWER 5 OF 8 SCISEARCH COPYRIGHT (c) 2006 The Thomson Corporation on STN
ACCESSION NUMBER: 1999:88596 SCISEARCH Full-text
THE GENUINE ARTICLE: 160TX
TITLE: [Difluro(phosphono)methyl]phenylalanine-containing peptide inhibitors of protein tyrosine phosphatases
AUTHOR: Desmarais S; Friesen R W; Zamboni R; Ramachandran C (Reprint)
CORPORATE SOURCE: Merck Frosst Canada Inc, Merck Frosst Ctr Therapeut Res, Dept Biochem & Mol Biol, POB 1005, Pointe Claire, PQ H9R 4P8, Canada (Reprint); Merck Frosst Canada Inc, Merck Frosst Ctr Therapeut Res, Dept Biochem & Mol Biol, Pointe Claire, PQ H9R 4P8, Canada; Merck Frosst Canada Inc, Merck Frosst Ctr Therapeut Res, Dept Med Chem, Pointe Claire, PQ H9R 4P8, Canada
COUNTRY OF AUTHOR: Canada
SOURCE: BIOCHEMICAL JOURNAL, (15 JAN 1999) Vol. 337, Part 2, pp. 219-223.
ISSN: 0264-6021.
PUBLISHER: PORTLAND PRESS, 59 PORTLAND PLACE, LONDON W1N 3AJ, ENGLAND
DOCUMENT TYPE: Article; Journal
LANGUAGE: English
REFERENCE COUNT: 40
ENTRY DATE: Entered STN: 1999
Last Updated on STN: 1999
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

AB Peptides containing the non-hydrolysable phosphotyrosine analogue 4-[difluro(phosphono)methyl]phenylalanine [Phe(CF2P)] were synthesized and tested as inhibitors of the protein tyrosine phosphatases (PTPs) PTP1B, CD45, PTP beta, LAR and SHP-1. identified peptides containing two adjacent Phe(CF2P) residues as potent inhibitors of PTPs. The tripeptide having the sequence Glu-Phe(CF2P)-Phe(CF2P) is a potent and selective inhibitor of PTP 1B. This peptide inhibits PTP1B with an IC50 of 40 nM, which is at least 100-fold lower than with other PTPs. A second tripeptide, Pro-Phe(CF2P)-Phe(CF2P), is most potent against PTP beta, with an IC50 of 200 nM, and inhibits PTP1B with an IC50 of 300 nM. These data suggest that it is possible to develop selective, active-site-directed, reversible, potent inhibitors of PTPs.

L29 ANSWER 6 OF 8 SCISEARCH COPYRIGHT (c) 2006 The Thomson Corporation on STN
ACCESSION NUMBER: 1998:495221 SCISEARCH Full-text
THE GENUINE ARTICLE: ZW771
TITLE: Inhibition of protein tyrosine phosphatases PTP1B and CD45 by sulfotyrosyl peptides

AUTHOR: Desmarais S; Jia Z C; Ramachandran C (Reprint)
CORPORATE SOURCE: Merck Frosst Canada Inc, Merck Frosst Ctr Therapeut Res, Dept Biochem & Mol Biol, POB 1005, Pointe Claire, PQ H9R 4P8, Canada (Reprint); Merck Frosst Canada Inc, Merck Frosst Ctr Therapeut Res, Dept Biochem & Mol Biol, Pointe Claire, PQ H9R 4P8, Canada; Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada
COUNTRY OF AUTHOR: Canada
SOURCE: ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, (15 JUN 1998) Vol. 354, No. 2, pp. 225-231.
ISSN: 0003-9861.
PUBLISHER: ACADEMIC PRESS INC, 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA.
DOCUMENT TYPE: Article; Journal
LANGUAGE: English
REFERENCE COUNT: 27
ENTRY DATE: Entered STN: 1998
Last Updated on STN: 1998
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

AB Sulfotyrosyl peptides corresponding to the known high-affinity substrate phosphotyrosyl peptide sequences in casein and the autophosphorylation sites of insulin receptor and EGF receptor were investigated as inhibitors of protein tyrosine phosphatases PTP1B and CD45. These peptides inhibit both PTP1B and CD45 in the micromolar range competitively and reversibly. The elements required for inhibition were investigated by truncation and substitution of these peptides. Acidic residues N-terminal to the sulfotyrosyl residues are essential for high-affinity binding to PTP1B. The recognition elements required for inhibition of PTP1B and CD45 are different and this suggests the possibility of identifying selective active-site-directed inhibitors for these enzymes. (C) 1998 Academic Press.

L29 ANSWER 7 OF 8 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
ACCESSION NUMBER: 94082074 EMBASE Full-text
DOCUMENT NUMBER: 1994082074
TITLE: Characterization and kinetic analysis of the intracellular domain of human protein tyrosine phosphatase β (HPTPβ) using synthetic phosphopeptides.
AUTHOR: Harder K.W.; Owen P.; Wong L.K.H.; Aebersold R.; Clark-Lewis I.; Jirik F.R.
CORPORATE SOURCE: Biomedicai Research Centre, University of British Columbia, 2222 Health Sciences Mall,Vancouver, BC V6T 1Z3, Canada
SOURCE: Biochemical Journal, (1994) Vol. 298, No. 2, pp. 395-401. .
ISSN: 0264-6021 CODEN: BIJOAK
COUNTRY: United Kingdom
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 029 Clinical Biochemistry
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 30 Mar 1994
Last Updated on STN: 30 Mar 1994

AB The intracellular domain of human protein tyrosine phosphatase β (HPTPβ) (44 kDa) was expressed in bacteria, purified using epitope 'tagging' immunoaffinity chromatography, and characterized with respect to kinetic profile, substrate specificity and potential modulators of enzyme activity. A chromogenic assay based on the Malachite Green method was employed for the detection of inorganic phosphate (P(i)) released from phosphopeptides by HPTPβ. This assay, modified so as to improve its sensitivity, was adapted to a 96-well microtitre plate format, and provided linear detection between 50 and 1000 pmol of P(i). The cytoplasmic domain of HPTPβ was strongly inhibited by vanadate, molybdate, heparin, poly(Glu, Tyr) (4:1) and zinc ions. In order to explore the substrate preferences of this PTPase, we generated 13-residue synthetic phosphotyrosine-containing peptides that corresponded to sites of physiological tyrosine phosphorylation. HPTPβ demonstrated k(cat.) values between 76 and 258 s-1 using four different phosphopeptides. The substrate preference of HPTPβ was in the order src(Tyr-527) > PDGF-R(Tyr-740) > ERK1(Tyr-204) >> CSF-1R(Tyr-708) with K(m) values ranging from 140 μM to greater than 10 mM. The variations in affinity were probably due to differences among the four phosphopeptides compared, particularly with respect to the character of the charged amino acids flanking the phosphotyrosine residue.

L29 ANSWER 8 OF 8 MEDLINE on STN DUPLICATE 1
ACCESSION NUMBER: 93306206 MEDLINE Full-text
DOCUMENT NUMBER: PubMed ID: 8318901
TITLE: Substrate specificities of catalytic fragments of protein tyrosine phosphatases (HPTP beta, LAR, and CD45) toward phosphotyrosylpeptide substrates and thiophosphotyrosylated peptides as inhibitors.
AUTHOR: Cho H; Krishnaraj R; Itoh M; Kitas E; Bannwarth W; Saito H; Walsh C T
CORPORATE SOURCE: Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02115.
SOURCE: Protein science : a publication of the Protein Society, (1993 Jun) Vol. 2, No. 6, pp. 977-84.
Journal code: 9211750. ISSN: 0961-8368.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199308
ENTRY DATE: Entered STN: 19930813
Last Updated on STN: 19970203
Entered Medline: 19930805

AB The transmembrane PTPase HPTP beta differs from its related family members in having a single rather than a tandemly duplicated cytosolic catalytic domain. We have expressed the 354-amino acid, 41-kDa human PTP beta catalytic fragment in Escherichia coli, purified it, and assessed catalytic specificity with a series of pY peptides. HPTP beta shows distinctions from the related LAR PTPase and T cell CD45 PTPase domains: it recognizes phosphotyrosyl peptides of 9-11 residues from lck, src, and PLC gamma with Km values of 2, 4, and 1 microM, some 40-200-fold lower than the other two PTPases. With kcat values of 30-205 s-1, the catalytic efficiency, kcat/Km, of the HPTP beta 41-kDa catalytic domain is very high, up to 5.7 x 10(7) M-1 s-1. The peptides corresponding to PLC gamma (766-776) and EGFR (1,167-1,177) phosphorylation sites were used for structural variation to assess pY sequence context recognition by HPTP beta catalytic domain. While exchange of the alanine residue at the +2 position of the PLC gamma (Km of 1 microM) peptide to lysine or aspartic acid showed little or no effect on substrate affinity, replacement by arginine increased the Km 35-fold. Similarly, the high Km value of the EGFR pY peptide (Km of 104 microM) derives largely from the arginine residue at the +2 position of the peptide, since arginine to alanine single mutation at the -2 position of the EGFR peptide decreased the Km value 34-fold to 3 microM. Three thiophosphotyrosyl peptides have been prepared and act as substrates and competitive inhibitors of these PTPase catalytic domains.

```
=> s l21 and (x-ray or crystal)
L30          0 FILE MEDLINE
L31          2 FILE CAPLUS
L32          2 FILE SCISEARCH
L33          0 FILE LIFESCI
L34          0 FILE BIOSIS
L35          0 FILE EMBASE

TOTAL FOR ALL FILES
L36          4 L21 AND (X-RAY OR CRYSTAL)

=> dup rem l36
PROCESSING COMPLETED FOR L36
L37          4 DUP REM L36 (0 DUPLICATES REMOVED)

=> d ibib abs 1-4
```

L37 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:331682 CAPLUS Full-text
DOCUMENT NUMBER: 140:352651
TITLE: The three-dimensional structure of protein tyrosine phosphatase β subunit and its use in drug design
INVENTOR(S): Evdokimov, Artem Gennady; Pokross, Matthew Eugene
PATENT ASSIGNEE(S): The Procter & Gamble Company, USA
SOURCE: U.S. Pat. Appl. Publ., 335 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2004077065	A1	20040422	US 2003-634027		20030804
PRIORITY APPLN. INFO.:			US 2002-413547P	P	20020925

AB The crystal structures of the catalytic domain of the human protein tyrosine phosphatase HPTPβ, in ligand-bound and ligand-free forms are described. These structures are useful in computer aided drug design for identifying compds. that bind or activate HPTPbeta and thereby modulate angiogenesis mediated disorders or diseases.

L37 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:580622 CAPLUS Full-text
DOCUMENT NUMBER: 140:87438
TITLE: Mechanism of insulin sensitization by BMOV (bis maltolato oxo vanadium); unliganded vanadium (VO4) as the active component
AUTHOR(S): Peters, Kevin G.; Davis, Mike G.; Howard, Brian W.; Pokross, Matthew; Rastogi, Vinit; Diven, Conrad; Greis, Kenneth D.; Eby-Wilkens, Elaine; Maier, Matthew; Evdokimov, Artem; Soper, Shari; Genbauffe, Frank
CORPORATE SOURCE: Cardiovascular Research, Procter & Gamble Pharmaceuticals, Health Care Research Center, Mason, OH, 45040, USA
SOURCE: Journal of Inorganic Biochemistry (2003), 96(2-3), 321-330
CODEN: JIBIDJ; ISSN: 0162-0134
PUBLISHER: Elsevier Science Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Organovanadium compds. have been shown to be insulin sensitizers in vitro and in vivo. One potential biochem. mechanism for insulin sensitization by these compds. is that they inhibit protein tyrosine phosphatases (PTPs) that neg. regulate insulin receptor activation and signaling. In this study, bismaltolato oxovanadium (BMOV), a potent insulin sensitizer, was shown to be a reversible, competitive phosphatase inhibitor that inhibited phosphatase activity in cultured cells and enhanced insulin receptor activation in vivo. NMR and x-ray crystallog. studies of the interaction of BMOV with two different phosphatases, HCPTPA (human low mol. weight cytoplasmic protein tyrosine phosphatase) and PTP1B (protein tyrosine phosphatase 1B), demonstrated uncomplexed vanadium (VO4) in the active site. Taken together, these findings support phosphatase inhibition as a mechanism for insulin sensitization by BMOV and other organovanadium compds. and strongly suggest that uncomplexed vanadium is the active component of these compds.
REFERENCE COUNT: 70 THERE ARE 70 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L37 ANSWER 3 OF 4 SCISEARCH COPYRIGHT (c) 2006 The Thomson Corporation on STN
ACCESSION NUMBER: 1998:495221 SCISEARCH Full-text
THE GENUINE ARTICLE: ZW771
TITLE: Inhibition of protein tyrosine phosphatases PTP1B and CD45 by sulfotyrosyl peptides
AUTHOR: Desmarais S; Jia Z C; Ramachandran C (Reprint)
CORPORATE SOURCE: Merck Frosst Canada Inc, Merck Frosst Ctr Therapeut Res, Dept Biochem & Mol Biol, POB 1005, Pointe Claire, PQ H9R 4P8, Canada (Reprint); Merck Frosst Canada Inc, Merck Frosst Ctr Therapeut Res, Dept Biochem & Mol Biol, Pointe Claire, PQ H9R 4P8, Canada; Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada
COUNTRY OF AUTHOR: Canada
SOURCE: ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, (15 JUN 1998) Vol. 354, No. 2, pp. 225-231.
ISSN: 0003-9861.
PUBLISHER: ACADEMIC PRESS INC, 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA.
DOCUMENT TYPE: Article; Journal
LANGUAGE: English
REFERENCE COUNT: 27

ENTRY DATE: Entered STN: 1998
Last Updated on STN: 1998
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

AB Sulfotyrosyl peptides corresponding to the known high-affinity substrate phosphotyrosyl peptide sequences in casein and the autophosphorylation sites of insulin receptor and EGF receptor were investigated as inhibitors of protein tyrosine phosphatases PTP1B and CD45. These peptides inhibit both PTP1B and CD45 in the micromolar range competitively and reversibly. The elements required for inhibition were investigated by truncation and substitution of these peptides. Acidic residues N-terminal to the sulfotyrosyl residues are essential for high-affinity binding to PTP1B. The recognition elements required for inhibition of PTP1B and CD45 are different and this suggests the possibility of identifying selective active-site-directed inhibitors for these enzymes. (C) 1998 Academic Press.

L37 ANSWER 4 OF 4 SCISEARCH COPYRIGHT (c) 2006 The Thomson Corporation on STN
ACCESSION NUMBER: 1998:125157 SCISEARCH Full-text
THE GENUINE ARTICLE: YW343
TITLE: Sequence-specific recognition of peptide substrates by the low M-r phosphotyrosine protein phosphatase isoforms
AUTHOR: Bucciantini M; Stefani M (Reprint); Taddei N; Chiti F; Rigacci S; Ramponi G
CORPORATE SOURCE: Univ Florence, Dept Biochem Sci, Viale Morgagni 50, I-50134 Florence, Italy (Reprint); Univ Florence, Dept Biochem Sci, I-50134 Florence, Italy
COUNTRY OF AUTHOR: Italy
SOURCE: FEBS LETTERS, (30 JAN 1998) Vol. 422, No. 2, pp. 213-217. ISSN: 0014-5793.
PUBLISHER: ELSEVIER SCIENCE BV, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS.
DOCUMENT TYPE: Article; Journal
LANGUAGE: English
REFERENCE COUNT: 32
ENTRY DATE: Entered STN: 1998
Last Updated on STN: 1998
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

AB A number of phosphotyrosine-containing peptides derived from the PDGF receptor phosphorylation sites have been synthesised. The peptides were assayed as substrates of the two isoforms (IF1 and IF2) of the low M-r PTPase. The calculated k(cat), K-m, and k(cat)/K-m values indicate that only one peptide is best hydrolysed by IF2 (but not IF1), whose catalytic efficiency averages those previously reported for most PTPases (except the Yersinia enzyme). This peptide is the only one containing a couple of no bulky hydrophobic residues at the phosphotyrosine N-side. The determination of the same catalytic parameters in the presence of analogues of the best hydrolysed peptide in which one or both hydrophobic residues were replaced by Asp or Lys residues confirmed the importance of the hydrophobic cluster at the phosphotyrosine N-side for optimal enzymatic hydrolysis. These findings are discussed in the light of the known IF2 X-ray structure. (C) 1998 Federation of European Biochemical Societies.

```
=> s human protein tyrosine phosphataseβ
L38          2 FILE MEDLINE
L39          2 FILE CAPLUS
L40          2 FILE SCISEARCH
L41          0 FILE LIFESCI
L42          2 FILE BIOSIS
L43          2 FILE EMBASE

TOTAL FOR ALL FILES
L44         10 HUMAN PROTEIN TYROSINE PHOSPHATASEB

=> dup rem l44
PROCESSING COMPLETED FOR L44
L45          2 DUP REM L44 (8 DUPLICATES REMOVED)

=> d ibib abs 1-2
```

L45 ANSWER 1 OF 2 MEDLINE on STN DUPLICATE 1
ACCESSION NUMBER: 95291173 MEDLINE Full-text
DOCUMENT NUMBER: PubMed ID: 7539661
TITLE: High-sensitivity determination of tyrosine-phosphorylated peptides by on-line enzyme reactor and electrospray ionization mass spectrometry.
AUTHOR: Amankwa L N; Harder K; Jirik F; Aebersold R
CORPORATE SOURCE: Biomedical Research Centre, University of British Columbia, Vancouver, Canada.
SOURCE: Protein science : a publication of the Protein Society, (1995 Jan) Vol. 4, No. 1, pp. 113-25.
Journal code: 9211750. ISSN: 0961-8368.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199507
ENTRY DATE: Entered STN: 19950720
Last Updated on STN: 19960129
Entered Medline: 19950713

AB We describe a simple, fast, sensitive, and nonisotopic bioanalytical technique for the detection of tyrosine-phosphorylated peptides and the determination of sites of protein tyrosine phosphorylation. The technique employs a protein tyrosine phosphatase micro enzyme reactor coupled on-line to either capillary electrophoresis or liquid chromatography and electrospray ionization mass spectrometry instruments. The micro enzyme reactor was constructed by immobilizing genetically engineered, metabolically biotinylated human protein tyrosine phosphatase beta onto the inner surface of a small piece of a 50-microns inner diameter, 360-microns outer diameter fused silica capillary or by immobilization of the phosphatase onto 40-90-microns avidin-activated resins. By coupling these reactors directly to either a capillary electrophoresis column or a liquid chromatography column, we were able to rapidly perform enzymatic dephosphorylation and separation of the reaction products. Detection and identification of the components of the reaction mixture exiting these reactors were done by mass analysis with an on-line electrospray ionization mass spectrometer. Tyrosine-phosphorylated peptides, even if present in a complex peptide mixture, were identified by subtractive analysis of peptide patterns generated with or without phosphatase treatment. Two criteria, namely a phosphatase-induced change in hydropathy and charge, respectively, and a change in molecular mass by 80 Da, were used jointly to identify phosphopeptides. We demonstrate that, with this technique, low picomole amounts of a tyrosine-phosphorylated peptide can be detected in a complex peptide mixture generated by proteolysis of a protein and that even higher sensitivities can be realized if more sensitive detection systems are applied.

L45 ANSWER 2 OF 2 MEDLINE on STN DUPLICATE 2
ACCESSION NUMBER: 94183168 MEDLINE Full-text
DOCUMENT NUMBER: PubMed ID: 8135747
TITLE: Characterization and kinetic analysis of the intracellular domain of human protein tyrosine phosphatase beta (HPTP beta) using synthetic phosphopeptides.
AUTHOR: Harder K W; Owen P; Wong L K; Aebersold R; Clark-Lewis I; Jirik F R
CORPORATE SOURCE: Biomedical Research Centre, University of British Columbia, Vancouver, Canada.
SOURCE: The Biochemical journal, (1994 Mar 1) Vol. 298 (Pt 2), pp. 395-401.
Journal code: 2984726R. ISSN: 0264-6021.
PUB. COUNTRY: ENGLAND: United Kingdom
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199404
ENTRY DATE: Entered STN: 19940428
Last Updated on STN: 19970203
Entered Medline: 19940415

AB The intracellular domain of human protein tyrosine phosphatase beta (HPTP beta) (44 kDa) was expressed in bacteria, purified using epitope 'tagging' immunoaffinity chromatography, and characterized with respect to kinetic profile, substrate specificity and potential modulators of enzyme activity. A chromogenic assay based on the Malachite Green method was employed for the detection of inorganic phosphate (Pi) released from phosphopeptides

by HPTP beta. This assay, modified so as to improve its sensitivity, was adapted to a 96-well microtitre plate format, and provided linear detection between 50 and 1000 pmol of Pi. The cytoplasmic domain of HPTP beta was strongly inhibited by vanadate, molybdate, heparin, poly(Glu, Tyr) (4:1) and zinc ions. In order to explore the substrate preferences of this PTPase, we generated 13-residue synthetic phosphotyrosine- containing peptides that corresponded to sites of physiological tyrosine phosphorylation. HPTP beta demonstrated kcat. values between 76 and 258 s-1 using four different phosphopeptides. The substrate preference of HPTP beta was in the order srcTyr-527 > PDGF-RTyr-740 > ERK1Tyr-204 >> CSF-1RTyr-708 with Km values ranging from 140 microM to greater than 10 mM. The variations in affinity were probably due to differences among the four phosphopeptides compared, particularly with respect to the character of the charged amino acids flanking the phosphotyrosine residue.

=> log y